However, the heterogeneous clinical course of endometrioid carcinoma is still an obstacle to individualized treatment.Mutations in the CTNNB1 exon 3 hotspot were suggested to be drivers of a more aggressive subtype of low-grade, early-stage endometrioid endometrial carcinoma [6–8]. Here, CTNNB1 is linked to endometrioid adenocarcinoma.